Sutro Biopharma (STRO) Stock Price, News & Analysis

Company Overview

Sutro Biopharma, Inc. is a clinical‐stage biotechnology company focused on developing innovative cancer therapies through its proprietary cell‐free protein synthesis platform, XpressCF®. This platform enables rapid production and optimization of novel biologics, including antibody‐drug conjugates (ADCs), bispecific antibodies and other protein modalities, with the goal of improving potency and manufacturability. By decoupling protein synthesis from living cells, XpressCF® offers researchers access to full control over protein composition, facilitating the design of homogeneous and high‐value therapies.

The company’s pipeline features several lead candidates in oncology indications. STRO‐001, an ADC targeting CD74, is being evaluated in patients with multiple myeloma and B‐cell malignancies. STRO‐002, another ADC directed against the folate receptor alpha, is under investigation in ovarian and endometrial cancers. Beyond these, Sutro is advancing a range of immuno‐oncology programs, including novel bispecific constructs that engage immune effector cells. Many of these programs are being developed both in‐house and in collaboration with global pharmaceutical partners.

Founded in 2003 and headquartered in South San Francisco, Sutro Biopharma serves a worldwide research and development community. The company has built a state‐of‐the‐art facility that integrates its XpressCF® lab capabilities with analytical and bioassay teams, allowing for end‐to‐end biologic design, screening and characterization. Sutro’s collaborative framework extends from academic institutions to major biopharmaceutical firms, reflecting its commitment to translating scientific innovation into potential therapies.

Leadership at Sutro includes CEO William Newell, who brings extensive experience in biotech commercialization and corporate strategy, and CSO Dr. Dennis Dougherty, a pioneer in chemical biology and protein engineering. Under their guidance, Sutro continues to refine its platform technology and expand its oncology pipeline, with the aim of bringing more precise and effective treatments to patients battling cancer.

Key Stats

• Today's Range: $0.76 to $0.83
• 50-Day Range: $0.68 to $1.05
• 52-Week Range: $0.52 to $5.17
• Volume: 229,298 shs
• Average Volume: 1.13 million shs
• Market Capitalization: $64.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.11
• Consensus Rating: Hold

Sutro Biopharma Stock Analysis - MarketRank™

Sutro Biopharma scored higher than 86% of companies evaluated by MarketBeat, and ranked 152nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Sutro Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Sutro Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sutro Biopharma is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sutro Biopharma has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.50% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sutro Biopharma has recently decreased by 51.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sutro Biopharma does not currently pay a dividend.

Dividend Growth

Sutro Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.70

Percentage of Shares Shorted

4.50% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sutro Biopharma has recently decreased by 51.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Sutro Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Sutro Biopharma is held by insiders.

Percentage Held by Institutions

96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STRO Stock Analysis - Frequently Asked Questions

How have STRO shares performed this year?

Sutro Biopharma's stock was trading at $1.84 at the beginning of the year. Since then, STRO stock has decreased by 58.6% and is now trading at $0.7615.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its earnings results on Thursday, May, 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.28. The business had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. Sutro Biopharma had a negative net margin of 373.66% and a negative trailing twelve-month return on equity of 347.60%.

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STRO
• CIK: 1382101
• Web: www.sutrobio.com
• Phone: (650) 392-8412
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sutro Biopharma: $6.11
• High Price Target: $17.00
• Low Price Target: $0.80
• Potential Upside/Downside: +702.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.46 million
• Net Margins: -373.66%
• Pretax Margin: -370.06%
• Return on Equity: -347.60%
• Return on Assets: -59.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.16
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: $66.43 million
• Price / Sales: 0.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 84,461,000
• Free Float: 81,420,000
• Market Cap: $64.32 million
• Optionable: Optionable
• Beta: 1.64